FULC Dec 2025 5.000 call
- GlobeNewswire
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced upcoming presentations to be made at the 31st Annual FSHD Society International Research Congress being held June 13-14, 2024 in Denver, Colorado, including an abstract outlining the baseline characteristics of patient
- GlobeNewswire
Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at Goldman Sachs’ 45th Annual Healthcare Conference on Monday, June 10th, 2024, at 10:00 a.m. ET. The webcast of the presentation will be accessible here and by visit
- Zacks
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
